PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: PIPELINE ANALYSIS PART 05: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Oral drugs - Market size and forecast 2018-2023 • Topical drugs - Market size and forecast 2018-2023 • Others - Market size and forecast 2018-2023 • Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Bayer AG • Eli Lilly and Company • Pfizer Inc. • Teva Pharmaceutical Industries Ltd. • VIVUS Inc. PART 15: APPENDIX • Research methodology • List of abbreviations PART 16: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Pipeline molecules for ED Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Oral drugs - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Oral drugs - Year-over-year growth 2019-2023 (%) Exhibit 22: Sales of VIAGRA and CIALIS 2016-2018 Exhibit 23: Topical drugs - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Topical drugs - Year-over-year growth 2019-2023 (%) Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions) Exhibit 26: Others - Year-over-year growth 2019-2023 (%) Exhibit 27: Market opportunity by product Exhibit 28: Customer landscape Exhibit 29: Market share by geography 2018-2023 (%) Exhibit 30: Geographic comparison Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 32: North America - Year-over-year growth 2019-2023 (%) Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Europe - Year-over-year growth 2019-2023 (%) Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Asia - Year-over-year growth 2019-2023 (%) Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 38: ROW - Year-over-year growth 2019-2023 (%) Exhibit 39: Key leading countries Exhibit 40: Market opportunity Exhibit 41: Impact of drivers and challenges Exhibit 42: Vendor landscape Exhibit 43: Landscape disruption Exhibit 44: Vendors covered Exhibit 45: Vendor classification Exhibit 46: Market positioning of vendors Exhibit 47: Bayer AG - Vendor overview Exhibit 48: Bayer AG - Business segments Exhibit 49: Bayer AG - Organizational developments Exhibit 50: Bayer AG - Geographic focus Exhibit 51: Bayer AG - Segment focus Exhibit 52: Bayer AG - Key offerings Exhibit 53: Eli Lilly and Company - Vendor overview Exhibit 54: Eli Lilly and Company - Business segments Exhibit 55: Eli Lilly and Company - Organizational developments Exhibit 56: Eli Lilly and Company - Geographic focus Exhibit 57: Eli Lilly and Company - Segment focus Exhibit 58: Eli Lilly and Company - Key offerings Exhibit 59: Pfizer Inc. - Vendor overview Exhibit 60: Pfizer Inc. - Business segments Exhibit 61: Pfizer Inc. - Organizational developments Exhibit 62: Pfizer Inc. - Geographic focus Exhibit 63: Pfizer Inc. - Segment focus Exhibit 64: Pfizer Inc. - Key offerings Exhibit 65: Teva Pharmaceutical Industries Ltd. - Vendor overview Exhibit 66: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 67: Teva Pharmaceutical Industries Ltd. - Organizational developments Exhibit 68: Teva Pharmaceutical Industries Ltd. - Geographic focus Exhibit 69: Teva Pharmaceutical Industries Ltd. - Segment focus Exhibit 70: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 71: VIVUS Inc. - Vendor overview Exhibit 72: VIVUS Inc. - Business segments Exhibit 73: VIVUS Inc. - Organizational developments Exhibit 74: VIVUS Inc. - Geographic focus Exhibit 75: VIVUS Inc. - Key offerings Exhibit 76: Validation techniques employed for market sizing

Bayer AG Eli Lilly and Company Pfizer Inc. Teva Pharmaceutical Industries Ltd. VIVUS Inc.